Financhill
Buy
75

CORT Quote, Financials, Valuation and Earnings

Last price:
$59.83
Seasonality move :
8.24%
Day range:
$61.59 - $64.25
52-week range:
$20.84 - $75.00
Dividend yield:
0%
P/E ratio:
50.29x
P/S ratio:
11.23x
P/B ratio:
10.39x
Volume:
1.3M
Avg. volume:
966.9K
1-year change:
173.97%
Market cap:
$6.6B
Revenue:
$482.4M
EPS (TTM):
$1.26

Analysts' Opinion

  • Consensus Rating
    Corcept Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $97.00, Corcept Therapeutics has an estimated upside of 53.07% from its current price of $63.37.
  • Price Target Downside
    According to analysts, the lowest downside price target is $67.00 representing 100% downside risk from its current price of $63.37.

Fair Value

  • According to the consensus of 2 analysts, Corcept Therapeutics has 53.07% upside to fair value with a price target of $97.00 per share.

CORT vs. S&P 500

  • Over the past 5 trading days, Corcept Therapeutics has underperformed the S&P 500 by -12.99% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Corcept Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Corcept Therapeutics has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Corcept Therapeutics reported revenues of $182.5M.

Earnings Growth

  • Corcept Therapeutics has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Corcept Therapeutics reported earnings per share of $0.41.
Enterprise value:
6.3B
EV / Invested capital:
--
Price / LTM sales:
11.23x
EV / EBIT:
43.66x
EV / Revenue:
9.96x
PEG ratio (5yr expected):
0.91x
EV / Free cash flow:
43.89x
Price / Operating cash flow:
49.51x
Enterprise value / EBITDA:
43.31x
Gross Profit (TTM):
$618.8M
Return On Assets:
21.04%
Net Income Margin (TTM):
22.56%
Return On Equity:
25.77%
Return On Invested Capital:
25.77%
Operating Margin:
25.53%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $397.6M $450M $628.6M $123.6M $182.5M
Gross Profit $392.4M $443.9M $618.8M $122M $179.7M
Operating Income $126.8M $98.1M $143.4M $31.2M $46.6M
EBITDA $130.2M $101.4M $144.5M $31.5M $47.1M
Diluted EPS $1.00 $0.81 $1.26 $0.28 $0.41
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $463.5M $401.9M $452.4M $431.5M $467M
Total Assets $534.1M $585.4M $533.3M $594M $784.3M
Current Liabilities $43M $44.8M $53.1M $121.9M $126.2M
Total Liabilities $44.4M $45.2M $59.9M $132.3M $145.4M
Total Equity $489.7M $540.2M $473.4M $461.7M $638.8M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $136.4M $154.5M $144.7M $52.9M $73.8M
Cash From Investing $43.4M $56.6M -$96.1M -$109.6M -$44M
Cash From Financing -$224.2M -$149.6M -$23M -$3.9M -$21.1M
Free Cash Flow $135.9M $154.4M $142.6M $52.9M $72.2M
CORT
Sector
Market Cap
$6.6B
$43.6M
Price % of 52-Week High
84.49%
47.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
173.97%
-34.6%
Beta (5-Year)
0.583
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $68.20
200-day SMA
Buy
Level $44.55
Bollinger Bands (100)
Buy
Level 48.21 - 63.29
Chaikin Money Flow
Buy
Level 57M
20-day SMA
Sell
Level $67.42
Relative Strength Index (RSI14)
Sell
Level 47.63
ADX Line
Sell
Level 46.55
Williams %R
Neutral
Level -73.0987
50-day SMA
Buy
Level $59.41
MACD (12, 26)
Buy
Level 1.66
25-day Aroon Oscillator
Buy
Level 76
On Balance Volume
Neutral
Level 148.3M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (20.488)
Buy
CA Score (Annual)
Level (2.1992)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.2957)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Stock Forecast FAQ

In the current month, CORT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CORT average analyst price target in the past 3 months is $97.00.

  • Where Will Corcept Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Corcept Therapeutics share price will rise to $97.00 per share over the next 12 months.

  • What Do Analysts Say About Corcept Therapeutics?

    Analysts are divided on their view about Corcept Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corcept Therapeutics is a Sell and believe this share price will drop from its current level to $67.00.

  • What Is Corcept Therapeutics's Price Target?

    The price target for Corcept Therapeutics over the next 1-year time period is forecast to be $97.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CORT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Corcept Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CORT?

    You can purchase shares of Corcept Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corcept Therapeutics shares.

  • What Is The Corcept Therapeutics Share Price Today?

    Corcept Therapeutics was last trading at $59.83 per share. This represents the most recent stock quote for Corcept Therapeutics. Yesterday, Corcept Therapeutics closed at $63.37 per share.

  • How To Buy Corcept Therapeutics Stock Online?

    In order to purchase Corcept Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

New Billion Dollar Contract Surprises GEO Analysts
New Billion Dollar Contract Surprises GEO Analysts

While earnings appeared mixed at first glance, management’s comments on…

Is Visa a Long-term Buy Now?
Is Visa a Long-term Buy Now?

There is something inherently attractive about buying a stock and…

Should You Sell Home Depot Before It’s Too Late?
Should You Sell Home Depot Before It’s Too Late?

The housing market is not out of the woods just…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 40x

Buy
55
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
44
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 34x

Alerts

Sell
41
CEVA alert for Feb 27

CEVA [CEVA] is down 12.85% over the past day.

Buy
78
HURN alert for Feb 27

Huron Consulting Group [HURN] is up 1.04% over the past day.

Sell
12
AAP alert for Feb 27

Advance Auto Parts [AAP] is down 2.07% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock